- Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors
- First natural killer cell-based cellular therapy study conducted in the continent of Africa
- Complete enrollment currently expected in Q1 2025
Friday, October 25, 2024
ImmunityBio Starts Phase 1 in CAR-NK Cell Therapy for Relapsed B-Cell Non-Hodgkin Lymphoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.